

Estimate change	↔
TP change	↑
Rating change	↔

Bloomberg	STARHEAL IN
Equity Shares (m)	588
M.Cap.(INRb)/(USDb)	313.8 / 3.3
52-Week Range (INR)	587 / 341
1, 6, 12 Rel. Per (%)	10/18/35
12M Avg Val (INR M)	463

#### Financials & Valuations (INR b)

Y/E March	2026	2027E	2028E
NEP	166.0	193.4	222.1
U/W Profit	-4.1	-2.9	-2.0
PBT	7.5	12.1	15.8
PAT	5.6	9.1	11.8

#### Ratios (%)

Claims	68.5	68.0	68.0
Commission	15.1	15.0	15.0
Expense	16.8	16.3	15.8
Combined	100.5	99.3	98.8
RoE	7.6	11.3	13.0
EPS (INR)	9.5	15.4	20.1
EPS Growth (%)	-13.9	63.2	30.2

#### Valuations

P/E (x)	56.2	34.4	26.4
P/BV (x)	4.1	3.7	3.2

#### Shareholding pattern (%)

As On	Mar-26	Dec-25	Mar-25
Promoter	58.0	58.0	57.7
DII	20.3	21.0	15.4
FII	15.1	14.1	18.7
Others	6.7	7.0	8.2

FII includes depository receipts

**CMP: INR533**

**TP: INR640 (+20%)**

**Buy**

### Underwriting performance strengthens

- Star Health (STARHEAL)'s net earned premium grew 14% YoY to INR43.3b (in line). For FY26, NEP grew 12% YoY to INR166b.
- The claims ratio at 64.8% (vs. our est. of 66.7%) improved 440bp YoY, the commission ratio at 14.2% (vs. our est. of 15.9%) declined 150bp YoY, and the expense ratio at 15.8% (vs. our est. of 13.6%) grew 160bp YoY. Robust underwriting performance led to a better-than-expected combined ratio of 94.8% (our estimate of 96.1%), which improved 440bp YoY.
- The underwriting loss of INR1.5b was lower than our estimate, while investment income was largely in line, leading to a 9% PAT beat at INR1.1b. For FY26, PAT declined 14% YoY to INR5.6b.
- The claims ratio is expected to maintain an improving trajectory, supported by price hikes and severity control through scaling up of prevention and wellness initiatives.
- We have largely maintained our IFRS estimates, considering a strong underwriting performance witnessed in 4QFY26. We expect IFRS PAT to post a 32% CAGR over FY26-28. **We reiterate our BUY rating with a TP of INR640 (based on 24x FY28E IFRS PAT).**

### Fresh business growth supported by the new-to-insurance customers

- Gross written premium at INR59.7b grew 16% YoY, driven by a 19% YoY growth in retail health premium and offset by a 28% YoY decline in group health premium. For FY26, GWP grew 11% YoY to INR186.2b.
- The renewal premium ratio was 99% in FY26 (vs. 97% in FY25). Fresh business in the retail health segment grew 37% YoY to INR45.7b for FY26.
- The underwriting loss for 4QFY26 came in at INR1.5b (vs. our estimate of INR1.8b), compared to the underwriting loss of INR2.8b in 4QFY25. As per IFRS accounting, STARHEAL reported an underwriting profit of INR2.1b in FY26 compared to an underwriting loss of INR1.7b in FY25.
- The IFRS retail claims ratio improved to 64.8% in 4QFY26 (67.8% in 4QFY25), led by price hikes, fresh business growth, and reduced claim frequency. The group health claims ratio improved to 73.5% in 4QFY26 (from 87.3% in 4QFY25), driven by a calibrated approach in the segment towards profitable SME cohorts.
- The improvement in IFRS claims ratio from 68.2% in 4QFY25 to 64.6% in 4QFY26 was slightly offset by a rise in expense ratio from 30.1% in 4QFY25 to 31.1% in 4QFY26, resulting in a combined ratio of 95.7% in 4QFY26 (98.3% in 4QFY25). For FY26, the IFRS combined ratio improved to 98.4% (100.7% in FY25).
- The insurer experienced a loss of ~INR600m as per IFRS accounting in 4QFY26. For FY26, IFRS PAT was at INR9.1b (+16% YoY) with an RoE of 10%. Adjusting for a normalized yield of 8%, IFRS PAT would have grown 45% YoY to INR12.2b with an RoE of 13.1%.
- STARHEAL's AUM grew to INR210b at the end of FY26 compared to INR183b at the end of FY25, with investment leverage at 2.1x. Investment yield declined to 5.8% (7.6% in FY25) due to negative equity market movements leading to MTM losses.
- The solvency ratio was largely stable at 2.1x.

- About 91% of the business came from proprietary channels, with STARHEAL having 830,000 agents and 924 branches. The target is to reach 1m+ agents in the next 2 years. Agency productivity grew 18% YoY to 410,000 in FY26, with 19% YoY growth in retail GWP and 8% YoY growth in fresh policies.

#### Key takeaways from the management commentary

- Due to higher contribution from long-term products and the 1/n accounting impact, NEP growth is expected to lag in the near term but should normalize in subsequent quarters.
- Investments in prevention and wellness initiatives (telemedicine, home healthcare, and condition management programs) have scaled significantly, with ~9x increase in usage in 4QFY26, supporting loss ratio improvement.
- Renewal book performance is improving, aided by pricing actions, with ~80% of the book expected to be repriced by 1QFY27.

#### Valuation and view

- Premium growth in 4QFY26 has been strong, especially in the retail health segment, backed by GST exemption. We remain optimistic about the overall prospects for Star Health, backed by 1) consistent growth in retail health, 2) improving agency and banca productivity, and 3) steady growth in specialized products and deepening presence. We believe that Star Health can deliver long-term growth with the investments made in profitable channels and products.
- The IFRS claims ratio is likely to improve and stabilize at ~68%, driven by the rising sum assured as well as price hikes. Continued operational efficiency will lead to an improved combined ratio in the long term.
- We broadly retain our IFRS estimates, considering a strong underwriting performance witnessed in 4QFY26. We expect IFRS PAT to post a 32% CAGR over FY26-28. **We reiterate our BUY rating with a TP of INR640 (based on 24x FY28E IFRS PAT).**

**Quarterly Performance**

(INR b)

Y/E March	FY25				FY26				FY25	FY26	4Q FY26E	Act v/s Est. (%)	YoY	QoQ
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q						
Gross premium	34.8	43.7	38.0	51.4	36.1	44.2	46.2	59.7	167.8	186.2	60.1	-0.8	16%	29%
Net written premium	31.7	39.8	35.6	48.2	34.6	42.3	43.6	56.0	155.3	176.5	56.7	-1.3	16%	28%
Net earned premium	35.2	37.0	38.0	38.0	39.4	40.8	42.5	43.3	148.2	166.0	44.8	-3.4	14%	2%
Investment Income	1.7	2.1	2.0	1.9	1.8	1.8	1.9	2.2	7.7	7.7	2.1	3.3	16%	12%
<b>Total Income</b>	<b>36.9</b>	<b>39.1</b>	<b>40.0</b>	<b>39.9</b>	<b>41.2</b>	<b>42.7</b>	<b>44.4</b>	<b>45.5</b>	<b>155.9</b>	<b>173.7</b>	<b>46.9</b>	<b>-3.1</b>	<b>14%</b>	<b>2%</b>
Change YoY (%)	15.7	16.6	15.8	11.5	11.5	9.0	11.1	14.0	14.8	11.4	17.7			
Incurring claims	23.8	27.0	27.1	26.3	27.4	29.2	29.1	28.1	104.2	113.8	29.9	-6.1	7%	-4%
Net commission	4.3	5.5	5.0	7.6	5.1	6.9	6.8	7.9	22.4	26.7	9.0	-12.1	4%	16%
Employee expense	3.7	4.5	4.1	4.6	3.9	4.4	5.2	6.3	16.9	19.8	5.1	23.8	37%	21%
Other expenses	2.0	2.0	2.2	2.3	2.3	2.4	2.6	2.6	8.5	9.8	2.6	-2.7	13%	-2%
Total Operating Expenses	33.8	39.0	38.5	40.7	38.7	42.8	43.8	44.8	152.0	170.1	46.6	-3.8	10%	2%
Change YoY (%)	16.6	18.7	21.1	16.8	14.4	9.9	13.7	10.0	18.3	11.9	14.4			
<b>Underwriting profit</b>	<b>1.4</b>	<b>-1.9</b>	<b>-0.5</b>	<b>-2.8</b>	<b>0.7</b>	<b>-2.0</b>	<b>-1.2</b>	<b>-1.5</b>	<b>-3.8</b>	<b>-4.1</b>	<b>-1.8</b>	<b>-13.7</b>	<b>NA</b>	<b>23%</b>
Operating profit	3.1	0.2	1.5	-0.9	2.5	-0.2	0.7	0.6	3.9	3.6	0.3	97.4	NA	-8%
<b>Shareholder's P/L</b>														
Transfer from Policyholder's	3.1	0.2	1.5	-0.9	2.5	-0.2	0.7	0.6	3.9	3.6	0.3	97.4	NA	-8%
Investment income	1.3	1.5	1.5	1.0	1.2	1.2	1.2	1.1	5.2	4.6	1.2	-13.6	5%	-14%
<b>Total Income</b>	<b>4.4</b>	<b>1.6</b>	<b>3.0</b>	<b>0.1</b>	<b>3.7</b>	<b>1.0</b>	<b>1.9</b>	<b>1.7</b>	<b>9.1</b>	<b>8.3</b>	<b>1.6</b>	<b>9.5</b>	<b>NA</b>	<b>-12%</b>
<b>Total Expenses</b>	<b>0.1</b>	<b>0.1</b>	<b>0.1</b>	<b>0.2</b>	<b>0.2</b>	<b>0.2</b>	<b>0.2</b>	<b>0.2</b>	<b>0.5</b>	<b>0.7</b>	<b>0.2</b>	<b>3.3</b>	<b>26%</b>	<b>-1%</b>
<b>PBT</b>	<b>4.3</b>	<b>1.5</b>	<b>2.9</b>	<b>-0.0</b>	<b>3.5</b>	<b>0.8</b>	<b>1.7</b>	<b>1.5</b>	<b>8.6</b>	<b>7.5</b>	<b>1.4</b>	<b>10.3</b>	<b>NA</b>	<b>-13%</b>
Change YoY (%)	10.9	-11.0	-26.0	NA	-17.4	-47.8	-39.6	NA	-23.7	-12.4	NA			
Tax Provisions	1.1	0.4	0.7	-0.0	0.9	0.2	0.5	0.4	2.2	2.0	0.3	14.6	NA	-12%
<b>Net Profit</b>	<b>3.2</b>	<b>1.1</b>	<b>2.2</b>	<b>0.0</b>	<b>2.6</b>	<b>0.5</b>	<b>1.3</b>	<b>1.1</b>	<b>6.5</b>	<b>5.6</b>	<b>1.0</b>	<b>8.9</b>	<b>NA</b>	<b>-13%</b>
Change YoY (%)	10.8	-11.2	-25.7	-99.6	-17.7	-50.7	-40.4	na	-24%	-14%	na			
<b>Key Parameters (%)</b>														
Share in GWP														
Health-Retail	89.2	90.0	93.0	94.4	93.9	95.7	94.2	96.6	92.2	95.3	96.9		2.3	2.4
Health-Group	9.5	8.0	5.7	4.0	4.8	4.2	3.8	2.5	6.6	3.7	2.4		-1.5	-1.3
PA	1.3	2.0	1.3	1.6	1.0	0.9	1.0	0.8	1.1	0.9	1.0		-0.8	-0.1
Claims ratio	67.6	72.8	71.4	69.2	69.5	71.5	68.5	64.8	70.3	68.5	66.7	-185bp	-442bp	-372bp
Commission ratio	13.5	13.8	14.1	15.8	14.7	16.3	15.6	14.2	14.4	15.1	15.9	-174bp	-161bp	-148bp
Expense ratio	18.1	16.4	17.7	14.2	17.9	16.0	17.9	15.8	16.4	16.8	13.6	222bp	160bp	-210bp
Combined ratio	99.2	103.0	103.3	99.2	102.2	103.8	102.1	94.8	101.1	100.5	96.1	-138bp	-442bp	-730bp
Solvency	2.3	2.2	2.2	2.2	2.2	2.2	2.1	2.1	2.1	2.2	-			

**Key Performance Indicators**

INRb	FY25	FY26	Change	4QFY25	4QFY26	Change
<b>IGAAP (Without 1/n)</b>						
Retail health retention	97.0%	99.0%	2.0%	94.0%	99.0%	5.0%
Expense ratio	29.9%	30.3%	0.4%	28.3%	28.6%	0.3%
Combined ratio	100.2%	98.8%	-1.4%	97.5%	93.4%	-4.1%
<b>IGAAP</b>						
Expense ratio	30.8%	31.9%	1.1%	29.9%	29.9%	0.0%
Combined ratio	101.1%	100.4%	-0.7%	99.2%	94.7%	-4.5%
<b>IFRS</b>						
Loss ratio	70.7%	68.7%	-2.0%	69.2%	65.2%	-4.0%
Expense ratio	30.4%	30.1%	-0.3%	29.2%	30.5%	1.3%
Combined ratio	101.1%	98.8%	-2.3%	98.4%	95.7%	-2.7%

Source: MOFSL, Company

**IFRS P&L**

INRm	FY24	FY25	FY26	FY27E	FY28E
<b>Insurance revenue</b>	<b>1,36,630</b>	<b>1,59,430</b>	<b>1,79,990</b>	<b>2,08,788</b>	<b>2,42,195</b>
% YoY growth		16.7	12.9	16.0	16.0
Insurance Service Expense	90,870	1,11,340	1,22,740	1,41,976	1,64,692
Deferred acquisition cost	32,160	37,370	42,400	49,692	57,642
Net expenses from reinsurance	1,080	1,590	1,540	1,786	2,072
<b>Insurance service result</b>	<b>12,520</b>	<b>9,130</b>	<b>13,310</b>	<b>15,334</b>	<b>17,788</b>
Investment income	11,730	12,620	10,910	16,695	18,724
Other operating expenses	9,260	10,800	10,925	12,451	14,113
Finance costs	190	410	950	1,140	1,368
PBT	14,800	10,540	12,345	18,438	21,031
Tax	3,760	2,670	3,235	4,610	5,258
<b>PAT</b>	<b>11,040</b>	<b>7,870</b>	<b>9,110</b>	<b>13,829</b>	<b>15,773</b>
EPS	18.9	13.4	15.5	23.5	26.8

Source: MOFSL, Company



**Key takeaways from the management commentary**

**Performance**

- Fresh retail growth stood at 38% YoY in 4QFY26, driven by both value and volume, with retail health policies growing 11% YoY.
- 90,000+ telemedicine calls were handled during the year, with ~40,000 pure telemedicine consultations.
- The new-to-insurance segment remains a key focus, with contribution increasing to ~93-94%, while portability contribution has declined.
- The company has taken a calibrated approach by slowing growth in select geographies.
- Management targets sustainable high-teen growth and mid-to-high teen RoE.
- The senior citizen segment accounts for ~20% of the portfolio. Alongside this, productivity initiatives have improved efficiency, leading to better commission ratios.
- The company will continue annual price revisions while maintaining focus on customer experience optimization.
- Retention remains strong at ~86–87% (volume basis), with further scope for improvement while remaining among the best in the industry.
- Due to higher contribution from long-term products and 1/n accounting impact, NEP growth is expected to lag in the near term but should normalize in subsequent quarters.

- The group health strategy has been recalibrated to prioritize profitability, resulting in improved loss ratios. The SME segment contributes ~78% of the group business, with a focus on profitable cohorts.

#### **Loss Ratio**


- Loss ratio improvement continued for the third consecutive quarter, with retail loss ratio improving to 64.8% in 4QFY26. Further improvement is expected going forward.
- Investments in prevention and wellness initiatives (telemedicine, home healthcare, condition management programs) have scaled significantly, with ~9x increase in usage in 4QFY26, supporting loss ratio improvement.
- Higher contribution from fresh retail business has improved portfolio mix, aiding loss ratio performance. Pricing actions are also expected to support a sustained improvement trajectory.
- Claim frequency has improved YoY, supported by telemedicine initiatives. Renewal book performance is also improving, aided by pricing actions, with ~80% of the book expected to be repriced by 1QFY27.
- Management expects to grind retail loss ratios from ~68% toward 65–66% via modestly above-inflation hikes, severity control, and better SME-segment mix, keeping the combined ratio sub-100% structurally.

#### **Distribution**

- Agent base is expected to scale to ~1 million over the next two years, with ~100,000 agents added annually. Agent productivity has improved by ~30% for fresh business and ~18% for overall business.
- A strong agent value proposition is expected to support retention and stickiness.
- Bima Sugam platform aims to provide a unified, service-oriented marketplace offering affordable insurance products, enhancing customer access and experience.
- Digital channel witnessed 35% YoY growth in fresh GWP in FY26, with 78% contribution from digital D2C and 22% from digital partners.
- Banca business witnessed a decline of 8% YoY in FY26, but RM productivity grew 26% YoY, and banca partnerships increased to 81.


## Key exhibits

**Exhibit 1: Trends in gross premium**




Source: MOFSL, Company

**Exhibit 2: Share of retail health stood at 97% in 4QFY26**




Source: MOFSL, Company

**Exhibit 3: Incurred claims of INR28b in 4QFY26**




Source: MOFSL, Company

**Exhibit 4: Combined ratio on an improving trajectory**




Source: MOFSL, Company

**Exhibit 5: Underwriting loss at INR1.5b in 4QFY26**




Source: MOFSL, Company

**Exhibit 6: Trend in IGAAP PAT**




Source: MOFSL, Company

**Exhibit 7: IFRS PAT trends**



Source: MOFSL, Company

**Exhibit 8: 1-yr forward P/E**



Source: MOFSL

## Financials and valuations

Income Statement								(INR m)	
Y/E March	2020	2021	2022	2023	2024	2025	2026	2027E	2028E
Retail Health	58,252	82,075	1,00,870	1,19,475	1,39,512	1,54,130	1,77,430	2,09,367	2,40,773
Group Health	8,897	9,963	12,066	8,076	10,824	11,038	6,839	6,839	7,523
PA	1,337	1,489	1,685	1,939	2,117	1,897	1,704	2,045	2,352
<b>Total GDPI</b>	<b>68,651</b>	<b>93,885</b>	<b>1,14,635</b>	<b>1,29,525</b>	<b>1,52,545</b>	<b>1,67,814</b>	<b>1,86,219</b>	<b>2,18,251</b>	<b>2,50,647</b>
Change (%)	27.1	36.8	22.1	13.0	17.8	10.0	11.0	17.2	14.8
NWP	52,395	71,794	1,08,096	1,23,197	1,40,674	1,55,252	1,76,503	2,06,863	2,37,569
<b>NEP</b>	<b>46,841</b>	<b>46,266</b>	<b>98,092</b>	<b>1,12,616</b>	<b>1,29,383</b>	<b>1,48,222</b>	<b>1,65,967</b>	<b>1,93,417</b>	<b>2,22,127</b>
Change (%)	27.9	-1.2	112.0	14.8	14.9	14.6	12.0	16.5	14.8
Net claims	30,874	43,695	85,400	73,204	85,940	1,04,194	1,13,752	1,31,524	1,51,046
Net commission	3,404	5,857	14,922	16,828	18,596	22,407	26,733	31,029	35,635
Expenses	11,013	14,031	18,443	20,538	23,944	25,406	29,598	33,779	37,460
Employee expenses	8,526	11,765	13,436	14,537	16,122	16,929	19,832	22,608	24,869
Other expenses	2,487	2,266	5,007	6,001	7,823	8,477	9,767	11,171	12,591
<b>Underwriting Profit/(Loss)</b>	<b>1,550</b>	<b>-17,316</b>	<b>-20,673</b>	<b>2,046</b>	<b>903</b>	<b>-3,785</b>	<b>-4,116</b>	<b>-2,915</b>	<b>-2,015</b>
Investment income (PH)	1,639	2,505	4,796	5,014	6,407	7,718	7,742	10,254	11,982
Operating profit	3,303	-14,811	-15,877	7,061	7,309	3,933	3,626	7,339	9,967
Investment income (SH)	1,212	1,718	3,214	3,287	4,089	5,135	4,610	5,601	6,759
<b>PBT</b>	<b>4,062</b>	<b>-14,458</b>	<b>-14,024</b>	<b>8,264</b>	<b>11,289</b>	<b>8,611</b>	<b>7,543</b>	<b>12,118</b>	<b>15,781</b>
Tax	1,389	-3,601	-3,559	2,078	2,838	2,152	1,973	3,030	3,945
Tax rate (%)	34.2	24.9	25.4	25.1	25.1	25.0	26.2	25.0	25.0
<b>PAT</b>	<b>2,633</b>	<b>-10,857</b>	<b>-10,464</b>	<b>6,186</b>	<b>8,450</b>	<b>6,459</b>	<b>5,570</b>	<b>9,089</b>	<b>11,836</b>

Balance sheet								(INR m)	
Y/E March	2020	2021	2022	2023	2024	2025	2026	2027E	2028E
Equity Share Capital	4,906	5,481	5,755	5,817	5,853	5,878	5,884	5,884	5,884
Reserves & Surplus	14,132	29,516	40,285	59,839	60,429	64,359	70,008	79,097	90,933
<b>Net Worth</b>	<b>19,038</b>	<b>34,996</b>	<b>46,040</b>	<b>65,656</b>	<b>66,282</b>	<b>70,236</b>	<b>75,892</b>	<b>84,981</b>	<b>96,817</b>
FV change	31	-76	267	234	1,036	885	-380	885	974
Borrowings	2,500	2,500	7,200	4,700	4,700	4,700	4,700	4,700	4,700
Other liabilities	38,361	67,589	81,629	92,988	1,08,525	1,32,025	1,60,426	1,80,456	2,05,616
<b>Total Liabilities</b>	<b>59,930</b>	<b>1,05,010</b>	<b>1,35,136</b>	<b>1,63,577</b>	<b>1,80,543</b>	<b>2,07,846</b>	<b>2,40,638</b>	<b>2,71,021</b>	<b>3,08,107</b>
Investments (SH)	18,110	27,941	44,939	53,459	63,361	71,857	75,108	84,859	96,561
Investments (PH)	24,789	40,426	68,796	80,462	91,548	1,07,126	1,25,016	1,46,483	1,71,170
Net Fixed Assets	1,019	990	1,171	1,113	1,751	1,849	1,803	1,853	1,903
Def Tax Assets	70	4,213	7,767	5,689	3,582	3,512	3,561	3,561	3,561
Current Assets	9,827	12,650	6,828	8,444	12,990	16,817	20,715	24,279	27,882
Cash & Bank	6,114	18,790	5,635	14,410	7,312	6,684	14,436	9,988	7,030
<b>Total Assets</b>	<b>59,930</b>	<b>1,05,010</b>	<b>1,35,136</b>	<b>1,63,577</b>	<b>1,80,543</b>	<b>2,07,846</b>	<b>2,40,638</b>	<b>2,71,021</b>	<b>3,08,107</b>

E: MOFSL Estimates

## Financials and valuations

### Ratios

Y/E March	2020	2021	2022	2023	2024	2025	2026	2027E	2028E
GWP growth	27.1	36.8	22.1	13.0	17.8	10.0	11.0	17.2	14.8
NWP growth	26.9	37.0	50.6	14.0	14.2	10.4	13.7	17.2	14.8
<b>NEP growth</b>	<b>27.9</b>	<b>-1.2</b>	<b>112.0</b>	<b>14.8</b>	<b>14.9</b>	<b>14.6</b>	<b>12.0</b>	<b>16.5</b>	<b>14.8</b>
Claim ratio	65.9	94.4	87.1	65.0	66.4	70.3	68.5	68.0	68.0
Commission ratio	6.5	8.2	13.8	13.7	13.2	14.4	15.1	15.0	15.0
Expense ratio	21.0	19.5	17.1	16.7	17.0	16.4	16.8	16.3	15.8
<b>Combined ratio</b>	<b>93.4</b>	<b>122.1</b>	<b>117.9</b>	<b>95.3</b>	<b>96.7</b>	<b>101.1</b>	<b>100.5</b>	<b>99.3</b>	<b>98.8</b>
<b>Profitability Ratios (%)</b>									
RoE	16.8	-40.2	-25.8	11.1	12.8	9.5	7.6	11.3	13.0

Valuations	2020	2021	2022	2023	2024	2025	2026	2027E	2028E
BVPS (INR)	38.8	63.9	80.0	112.9	113.2	119.5	129.0	144.4	164.5
Change (%)	43.9	64.6	25.3	41.1	0.3	5.5	7.9	12.0	13.9
<b>Price-BV (x)</b>	<b>13.7</b>	<b>8.3</b>	<b>6.6</b>	<b>4.7</b>	<b>4.7</b>	<b>4.5</b>	<b>4.1</b>	<b>3.7</b>	<b>3.2</b>
EPS (INR)	5.4	-19.8	-18.2	10.6	14.4	11.0	9.5	15.4	20.1
Change (%)	15.8	-469.1	-8.2	-158.5	35.8	-23.9	-13.9	63.2	30.2
<b>Price-Earnings (x)</b>	<b>99.1</b>	<b>-26.9</b>	<b>-29.3</b>	<b>50.0</b>	<b>36.8</b>	<b>48.4</b>	<b>56.2</b>	<b>34.4</b>	<b>26.4</b>
<b>Market Cap/GDPI (x)</b>	<b>4.6</b>	<b>3.3</b>	<b>2.7</b>	<b>2.4</b>	<b>2.1</b>	<b>1.9</b>	<b>1.7</b>	<b>1.4</b>	<b>1.2</b>

E: MOFSL Estimates

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

**Disclosures**

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on [www.motilaloswal.com](http://www.motilaloswal.com) > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

**Regional Disclosures (outside India)**

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

**For Hong Kong:**

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

**For U.S.**

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

**For Singapore**

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh Rajani

Email: [nainesh.rajani@motilaloswal.com](mailto:nainesh.rajani@motilaloswal.com)

Contact: (+65) 8328 0276

**Specific Disclosures**

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.  
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.  
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report:No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.  
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.  
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
  - actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
  - received compensation/other benefits from the subject company in the past 12 months
  - any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
  - acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
  - be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
  - received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
  - Served subject company as its clients during twelve months preceding the date of distribution of the research report.
- The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report
- Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

**Analyst Certification**

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

**Terms & Conditions:**

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

**Disclaimer:**

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays. This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.